Europe
Rare disease giant Shire plunked down an undisclosed sum to get its hands on a preclinical autoimmune drug candidate being developed by AB Biosciences.
The FDA’s Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
During an international conference in Davos, Switzerland, President Donald Trump sat down with the leaders of several European life science companies to encourage more investment in the United States.
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
Joseph Jimenez retires at the end of the month after eight years in the top job at Novartis.
The company struck the cash-and-share deals to boost its presence in Europe.
TxCell today reports its fourth quarter 2017 financials and provides an update on its financing.
PRESS RELEASES